Text Size

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

This study has been completed.
Sponsor:
Information provided by:
Baskent University
ClinicalTrials.gov Identifier:
NCT00522470
First received: August 27, 2007
Last updated: May 7, 2008
Last verified: May 2008
History of Changes
  Purpose

We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.


Condition Intervention Phase
Type 2 Diabetes Mellitus
Obesity
 Drug: rosiglitazone
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels in Diabetic Women

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Baskent University:

  Eligibility

Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • newly diagnosed, drug naive women with type 2 diabetes

Exclusion Criteria:

  • presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)
  • presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00522470

Locations
Turkey
Baskent University Hospital Department of Endocrinology
Ankara, Bahçelievler, Turkey, 06490
Sponsors and Collaborators
Baskent University
Investigators
Principal Investigator: Zehra Berberoglu, MD Baskent University Faculty of Medicine
  More Information

No publications provided by Baskent University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00522470     History of Changes
Other Study ID Numbers: KA 06/299
Study First Received: August 27, 2007
Last Updated: May 7, 2008
Health Authority: Turkey: Ethics Committee

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Obesity
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Overnutrition
Nutrition Disorders
 Overweight
Body Weight
Signs and Symptoms
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013